News
Gilead Sciences is to continue pushing forward with its HIV drug after it achieves its primary objectives in phase 2 clinical trials. Leading biopharmaceutical company, Gilead Sciences, has announced that its phase 2 clinical trials evaluating…
Following the news that the British Medical Journal will no longer publish trial data unless completely transparent, find out what global pharma company GSK thinks about this vow. Global drug giant, GlaxoSmithKline, has responded to the news this morning that the British Medical Journal, from…
Leading global oncology R&D company, Astex Pharmaceuticals, has signed a multi-million drug discovery alliance deal with Cancer Research and Newcastle University. A major five-year strategic drug discovery alliance, to discover and develop new cancer drugs, has been formed by…
As Q3 financial results still trickle in, Bayer announces it has had an 11% increase in Group sales this quarter and that it has signed a merger agreement with leading vitamin company, Schiff Nutritional International. The Bayer Group remains on a path of growth, according to the pharmaceutical company’s latest…
Product sales at UCB Pharma have increased by 5% in the first nine months of 2012. UCB Pharma has released an interim report for the first three quarters of 2012, which showcases the…
ViiV Healthcare, formed by GSK and Pfizer, has revised its agreement with Shionogi, giving the Japanese company equity in exchange for exclusive global rights to its integrase inhibitor, dolutegravir. Japanese pharmaceutical group, Shionogi & Co is entering into an agreement with ViiV Healthcare, substantially revising…
The FDA has approved Teva’s Synribo for the treatment of chronic myelogenous leukemia in adult patients in the US. Teva Pharmaceuticals has announced that the US FDA has approved its drug, Synribo…
Mixed Q3 results for Merck are announced, as the company feels the effects of patent expirations on key drugs, but plans to launch new drugs in 2013 to offset generic competition. Merck has reported mixed financial results for the third quarter of 2012. The company’s profit increased…
Swiss drugmaker, Novartis, reports flat net profit for the third quarter of 2012 in the same week it defends the safety of its flu vaccines in Italy. Novartis has reported a net profit of $2.48 billion in the third quarter, which was more or less the same as…
